Basic Information
Mixtard
Regulatory Information
EMEA/H/C/000428
Authorised
October 7, 2002
April 25, 2002
20
January 24, 2024
Company Information
Denmark
Novo Allé DK-2880 Bagsvaerd
Novo Nordisk A/S
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of diabetes mellitus.
Overview Summary
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).